Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_assertion type Assertion NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_head.
- NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_assertion description "[High expression (score = 4) of CHFR is strongly associated with adverse outcomes: the risk for progressive disease after first-line chemotherapy with carboplatin-paclitaxel was 52% in patients with CHFR-high versus only 19% in those with CHFR-low tumors (P = 0.033).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_provenance.
- NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_assertion evidence source_evidence_literature NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_provenance.
- NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_assertion SIO_000772 23386692 NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_provenance.
- NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_assertion wasDerivedFrom befree-20140225 NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_provenance.
- NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_assertion wasGeneratedBy ECO_0000203 NP594379.RAuARdW3duGw_hyqa09YNHRtEktswS2XtlpUnzICxlavg130_provenance.